INCOG BioPharma is a fill/finish CDMO providing end-to-end solutions for clinical through commercial phase sterile injectable drug products for the global biopharmaceutical market. Our facility is FDA-approved and Annex 1-compliant and uses the latest technology to provide tailored manufacturing solutions. We fill high-value biologics and peptides into syringes, vials, and cartridges, and offer autoinjector assembly, final packaging solutions, and in-house analytics.

Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a 1,000 early-phase clinical trials, including for 45 therapies that were approved by the FDA or EMA. START represents the world’s largest roster of early-phase Principal Investigators (PIs) across its ten clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world. Learn more at STARTresearch.com.

Hera Health Solutions, Inc. is a pharmaceutical device company specializing in the research, development, and commercialization of long-acting therapeutics through a proprietary nanotechnology-enabled bioerodible drug delivery platform. Our advanced nanofiber-based system enables precise control of drug release kinetics and enhanced bioavailability. We partner with pharmaceutical and biotech companies to accelerate reformulation programs with scalable, GMP-ready manufacturing for rapid clinical and commercial translation, and actively co-develop and license innovative long-acting drug delivery solutions.

Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints. For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 30,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of all FDA drug approvals since 2012.

For more information, go to Clario.com or follow us on LinkedIn.

TesoRx Pharma and its subsidiary, Lipac Oncology, are clinical-stage companies utilizing a novel Neoliposomal™ delivery system. This delivery system addresses significant challenges like poor solubility, low permeability, and systemic toxicity, creating breakthrough therapies. Their primary clinical candidates are for intracavitary carcinomas (Lipac) and oral Testosterone Replacement Therapy (TRT) (TesoRx). TesoRx's TRT bypasses the liver via lymphatic absorption, demonstrating clinically enhanced bioavailability.

RheoTek Medical is advancing ultra-precise drug delivery technologies—needle and needle-free—designed to enhance accuracy, consistency, and patient outcomes across immunotherapy, vaccines, and pain management. Our platform addresses the critical need for controlled dosing and predictable delivery, expanding access to life-saving therapies and enabling new treatment possibilities in both clinical and decentralized settings.

Amcor is a global leader in packaging solutions for consumer and healthcare products. With industry-leading innovation capabilities, global scale and technical expertise, we help our customers grow and meet the needs of millions of consumers every day. Our teams develop responsible, more sustainable packaging in flexible and rigid formats across multiple materials. Supported by a commitment to safety, ~70,000 colleagues across ~140 countries bring our global capabilities to local customers and provide local access to global brands. Our work is guided by our purpose of elevating customers, shaping lives and protecting the future. NYSE: AMCR; ASX: AMC

Imagine Pharma is a biotechnology company focused on the development of its IMG-1® polypeptide. Research and development efforts have led to the creation of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine. Each platform comprises first-in-class programs that address multiple disease states in large, underserved markets.

Working, creating, together. We are convinced that in a world where new medicines, new practices and better therapeutic outcomes are constantly being sought, collaboration is the only way to efficiently reach these goals. Nanomi has developed the unique Microsieve technology that adds value to drug development programs of others. The technology is applicable to a wide range compounds and provides the most advanced solution for manufacture of uniform monodisperse biodegradable microspheres and nanoparticles for long-acting release medicines. Nanomi’s pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare. Nanomi is open to partnerships.

Ossianix Inc has developed highly selective and potent brain shuttles. We use the single domain VNAR antibody platform targeting the transferrin receptor and the amino acid transporter CD98 to produce industry leading brain shuttles that deliver therapeutic levels of a broad range of drugs to the CNS including antibodies, enzymes, peptides and oligonucleotides (ASO& siRNA). Our lead oligo programs are MAPT and alpha synuclein for neurodegenerative disease which are in pre clinical development.

Nelson Labs is a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We serve over 3,000 customers from 12 facilities in the United States, Mexico, Asia and Europe and offer a comprehensive array of over 900 laboratory tests along with the expertise of Regulatory Compliance Associates, a recognized leader in regulatory consulting for the life sciences industry. We support our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance.  We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Safeguarding Global Health® – with every test completed. Learn more: nelsonlabs.com.